UroGen Pharma Ltd.
9 Ha’Ta’asiya Street
Ra’anana 4365007, Israel
VIA EDGAR
October 24, 2018
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jeff Gabor
| Re: | UroGen Pharma Ltd. | |||
| Registration Statement on Form F-3 | ||||
| File No. 333-227811 | ||||
| Acceleration Request | ||||
| Requested Date: | Friday, October 26, 2018 | |||
| Requested Time: | 4:00 P.M. Eastern Daylight Time | |||
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form F-3 (File No. 333-227811) to become effective on October 26, 2018, at 4:00 p.m. Eastern Daylight Time, or as soon thereafter as is practicable.
If you have any questions regarding this request, please contact Charles J. Bair of Cooley LLP at (858) 550-6142 or Daniel I. Goldberg of Cooley LLP at (212) 479-6722. Thank you for your assistance with this matter.
| Sincerely, | ||
| UROGEN PHARMA LTD. | ||
| By: | /s/ Peter P. Pfreundschuh | |
| Peter P. Pfreundschuh | ||
| Chief Financial Officer | ||